Publications
45
Citations
1,754
Est. group size
~24
Recurring co-author estimate
Active years
39
Publishing since 1987
Donna Bucci's research focuses on blood cancers, particularly acute myeloid leukemia, and how certain drugs can selectively kill cancer cells. Recent work has examined a drug called ABT-199 (venetoclax), which blocks a protein (BCL-2) that helps cancer cells survive, as well as studies on brain tumor (glioma) treatment involving dexamethasone and bevacizumab. This research generally involves laboratory and clinical studies aimed at understanding drug mechanisms and improving cancer treatment strategies.
Publication output was low and irregular for most of the past decade but spiked sharply in 2023 before dropping off in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- P02.12.A DISTINCT MODULATION OF METABOLISM AND GLIOMA-ASSOCIATED MICROENVIRONMENT BY DEXAMETHASONE AND BEVACIZUMAB
Neuro-Oncology · 2025
- Supplementary Figure Legends from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Figures from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Methods from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Table 1 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Table 2 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Figure Legends from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Methods from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Table 1 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Table 2 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Supplementary Figures from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Data from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Data from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
2023
- Blood×4
- medRxiv×2
- Blood Advances×1
- Haematologica×1
- Journal of Hematology & Oncology×1
- Alice S. Mims
Medicine · The Ohio State University
- Daelynn R. Buelow
Medicine · The Ohio State University
- Uma Borate
Medicine · The Ohio State University
- Kieran Sahasrabudhe
Medicine · The Ohio State University
- Krzysztof Mrózek
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile